OncoSignal
Live from Open Targets Platform, fetched 2026-11-11 16:03 UTC. Every row links to its source record.

ZBTB17 zinc finger and BTB domain containing 17

ENSG00000116809 · protein coding · Open Targets profile

Transcription factor that can function as an activator or repressor depending on its binding partners, and by targeting negative regulators of cell cycle progression. Plays a critical role in early lymphocyte development, where it is essential to prevent apoptosis in lymphoid precursors, allowing them to survive in response to IL7 and undergo proper lineage commitment. Has been shown to bind to the promoters of adenovirus major late protein and cyclin D1 and activate transcription. Required for early embryonic development during gastrulation. Represses RB1 transcription; this repression can be blocked by interaction with ZBTB49 isoform 3/ZNF509S1 (PubMed:25245946). {ECO:0000269|PubMed:16142238, ECO:0000269|PubMed:19164764, ECO:0000269|PubMed:25245946, ECO:0000269|PubMed:9308237, ECO:0000269|PubMed:9312026}.

ZBTB17: inherited and tumour-mutation evidence across 15 cancers

Each row is a cancer, strongest overall evidence first. The two dots show how strong the inherited (germline) and tumour-mutation (somatic) evidence is; the line between them is the gap.

Inherited (germline) variantsMutations in tumours (somatic)
00.250.50.751hepatocellular carcinomahepatocellular carcinomaneuroblastomaneuroblastomaintrahepatic cholangiocarcinomaintrahepatic cholangiocarcinomamelanomamelanomaovarian carcinomaovarian carcinomaovarian cancerovarian cancerlymphomalymphomaprostate cancerprostate cancerprostate carcinomaprostate carcinomaFamilial prostate cancerFamilial prostate cancergastric cancergastric canceracute promyelocytic leukemiaacute promyelocytic leukemiatriple-negative breast carcinomatriple-negative breast carcinomacolorectal carcinomacolorectal carcinomaesophageal squamous cell carcinomaesophageal squamous cell carcinoma

Scores run from 0 (no evidence) to 1 (strongest). A missing dot at 0 means Open Targets holds no evidence of that kind. Source: Open Targets Platform, fetched live.

Tractability

Small molecule
High-Quality Pocket
PROTAC
UniProt Ubiquitination, Database Ubiquitination

gnomAD loss of function constraint: o/e 0.2818700075149536 (upper bound 0.39640000462532043). Low values mean loss of function is poorly tolerated, a safety flag for inhibition.

Who runs trials of these drugs

No named investigators on registry trials of ZBTB17's approved or late-stage drugs in the last three years.

No terminated, withdrawn or suspended trials of ZBTB17's drugs are registered

All 0 drugs and clinical candidates as a table

Each drug, stage and indication links to its Open Targets record, where the trials and approvals behind it are listed. Salt forms (for example a mesylate) are listed as Open Targets records them, as separate entries.

DrugTypeHighest stageIndicationsSource records
No drugs or clinical candidates recorded.